Ignyta to raise $40 million, move to NASDAQ

Cancer play Ignyta Inc. (OCTBB:RXDX) said it plans to raise up to $40 million in a follow-on and move its listing to NASDAQ. Leerink and Ladenburg Thalmann are underwriters. Ignyta's RXDX-101 is in a Phase I/II trial to treat solid tumors. The company has exclusive, worldwide rights from Nerviano Medical Sciences s.r.l. (Nerviano, Italy) to the oral c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), neurotrophic tyrosine kinase receptor 1 ( NTRK1; TrkA) and anaplastic lymphoma kinase (ALK) inhibitor. ...